title: Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
abstract: Adenocarcinoma of the pancreas is currently the fifth leading cause of death in the United States. It remains generally incurable by available treatment modalities. We report here on the characterization of a permanent pancreatic cell line (KCI-MOH1), established as a xenograft in severe combined immune deficient (SCID) mice, from a 74 year-old African American male patient diagnosed with pancreatic cancer. Sections from paraffin-embedded tumors excised from SCID mice revealed typical adenocarcinoma of the pancreas. Karyotypic analysis of cultured cells derived from tumors grown in SCID mice revealed a male karyotype with multiple clonal aberrations: 42, XY, add (3)(p11.2), der(7) t(7;12) (p22;q12), -10, -12, add (14)(p11), -18, add (20)(q13)-22/84, idemx2. Immunostaining of KCI-MOH1 tissues shows strong expression of p53 and p21 proteins. The xenograft model was established by transplanting the KCI-MOH1 cells subcutaneously (s.c.) in SCID mice. When the s.c. tumor was transplanted in vivo to other SCID mice, the success rate was 100%, with a doubling time of 8.5 days. The SCID mouse xenograft model was used to test the efficacy of selected standard chemotherapeutic drugs (taxol, gemcitabine, 5-fluorouracil, and Ara-C) and novel biological agents (Bryostatin 1 and Auristatin-PE). Results show that gemcitabine, Ara-C, and Bryostatin 1 were active against KCI-MOH1. The xenograft described herein can be used as an animal model to facilitate the development of novel therapeutic agents against human pancreatic cancers.
authors.affiliation: Department of Internal Medicine, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, Michigan 48201, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Mohammad
authors.forename: M C
authors.initials: MC
authors.lastname: Dugan
authors.forename: A N
authors.initials: AN
authors.lastname: Mohamed
authors.forename: V P
authors.initials: VP
authors.lastname: Almatchy
authors.forename: T M
authors.initials: TM
authors.lastname: Flake
authors.forename: S T
authors.initials: ST
authors.lastname: Dergham
authors.forename: A F
authors.initials: AF
authors.lastname: Shields
authors.forename: A A
authors.initials: AA
authors.lastname: Al-Katib
authors.forename: V K
authors.initials: VK
authors.lastname: Vaitkevicius
authors.forename: F H
authors.initials: FH
authors.lastname: Sarkar
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000235:genetics; D004195:Disease Models, Animal; D015870:Gene Expression; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D007621:Karyotyping; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; C493957:Cdkn1a protein, mouse; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins